FDA Clears Asuragen's RNA Preservation Device | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asuragen today announced that it has received US Food and Drug Administration clearance of its cGMP manufactured sample collection and cellular RNA preservation device.

The device called RNARetain was first cleared by FDA in 2007 in conjunction with Agendia's MammaPrint breast cancer test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.